Column Capital Advisors’s 10x Genomics TXG Stock Holding History

Column Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$109K	Hold	2,638	–	–	0.02%	207
2023 Q2	$147K	Buy	2,638 +386	+17%	+$20.9K	0.02%	168
2023 Q1	$126K	Buy	2,252 +363	+19%	+$17K	0.02%	193
2022 Q4	$68.8K	Hold	1,889	–	–	0.01%	256
2022 Q3	$54K	Hold	1,889	–	–	0.01%	264
2022 Q2	$85K	Buy	1,889 +707	+60%	+$36.7K	0.02%	217
2022 Q1	$90K	Buy	1,182 +264	+29%	+$23.1K	0.02%	214
2021 Q4	$137K	Buy	+918	New	+$141K	0.03%	163

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Column Capital Advisors's TXG Position: Q3 2023 in Review

Column Capital Advisors held its 10x Genomics (TXG) position steady in Q3 2023 at 2,638 shares worth $109K. The position accounts for 0.02% of the portfolio, ranked #207.

Column Capital Advisors first reported a position in TXG in Q4 2021 and has held it in 8 quarters since. The position peaked at $147K in Q2 2023. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

Column Capital Advisors held 2,638 shares of 10x Genomics worth $109K as of Q3 2023.
Column Capital Advisors left its 10x Genomics share count unchanged in Q3 2023.
10x Genomics made up 0.02% of Column Capital Advisors's portfolio in Q3 2023, its #207 holding.
Column Capital Advisors first reported a position in 10x Genomics in Q4 2021 and has held it in 8 quarters since.
Column Capital Advisors's 10x Genomics position peaked at $147K in Q2 2023.
256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.